I-05 Malte Selch Larsen Impact of trial designs, study conditions and statistical methods on the estimation of drug potency and power in clinical trials of haemophilia with inhibitors Wednesday 10:10-11:40 |
I-17 Felix Stader A population database for elderly to inform physiologically-based pharmacokinetic models considering anatomical, physiological and biological system parameters Wednesday 10:10-11:40 |
I-21 Sabine Stuebler Systems biology model of the mucosal immune system in the context of inflammatory bowel disease Wednesday 10:10-11:40 |
I-46 Tamara van Steeg Development of a mathematical model to elucidate the cross-linking of GSK-057 and ADAs and binding to TNFR1 receptor – filling the gap between hypothesis and reality. Wednesday 10:10-11:40 |
I-47 Rob van Wijk Nanoscale blood sampling from zebrafish larvae for the estimation of distribution volume and absolute clearance Wednesday 10:10-11:40 |
I-49 Diego Vera Disease modelling of repeated acute attacks in an acute intermittent porphyria mouse model Wednesday 10:10-11:40 |
I-55 Roeland Wasmann Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies Wednesday 10:10-11:40 |
I-69 Jurij Aguiar Zdovc The expression of ABCB1 gene influences the PK of rivaroxaban – a PK/PD study in patients with the total hip or knee arthroplasty Wednesday 10:10-11:40 |
I-71 Ying Zhang Exposure–Response Model and Development of a Shiny App of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients with Hereditary Angioedema (HAE) Wednesday 10:10-11:40 |
I-74 Li Zhang Mechanism-based Population PK/PD modeling of T lymphocytes Depletion and Repopulation Following Treatment with anti-CD52 Antibody GLD52 in Patients with Progressive Multiple Sclerosis Wednesday 10:10-11:40 |
II-04 Ruben Faelens Benefits of TDM in clinical management: a test case in infliximab for ulcerative colitis Wednesday 15:50-17:20 |
II-11 Chiara Fornari Development of a haematopoiesis systems pharmacology model for prediction of carboplatin induced bone marrow toxicity Wednesday 15:50-17:20 |
II-25 Anna Georgieva Kondic Integrated novel modelling framework for evaluating the efficacy and cost effectiveness of novel pharmaceutical agents in stroke prevention Wednesday 15:50-17:20 |
II-32 Kosalaram Goteti Drug-disease model describing the effect of intraarticular injected sprifermin on cartilage thickness measured by magnetic resonance imaging in osteoarthritis patients Wednesday 15:50-17:20 |
II-36 Hans Peter Grimm PK Projections for Therapeutic Proteins in Entry Into Human Studies: Roche pRED Experience From 2004 to 2016 Wednesday 15:50-17:20 |
II-37 Ana-Marija Grisic Towards a comprehensive PK/PD model of infliximab in inflammatory bowel diseases, with support of prior knowledge Wednesday 15:50-17:20 |
II-40 Emilie Hénin Individual therapeutic monitoring strategy of a factor IX concentrate (OCTAFIX ®) for prophylaxis in patients with haemophilia B, using population modelling approaches Wednesday 15:50-17:20 |
II-42 Eef Hoeben Modelling the Transfer of Sildenafil Across the Placenta with Data of an Ex-Vivo Human Placenta Perfusion Experiment Wednesday 15:50-17:20 |
II-43 Nick Holford Using Biomarkers to Predict the Target Dose of Warfarin and Linezolid Wednesday 15:50-17:20 |
II-54 Petra Jauslin Population Pharmacokinetic Analysis of Tildrakizumab, an Anti-IL-23 Antibody, in Healthy Volunteers and Subjects with Psoriasis Wednesday 15:50-17:20 |
II-55 Garrit Jentsch A repeated time-to-event model is superior to a count regression analysis in linking FVIII activity to bleeding events in prophylactically treated patients with severe haemophilia A Wednesday 15:50-17:20 |
II-58 Koen Jolling Population pharmacokinetic modelling of CHF6001 following dry powder inhalation in healthy volunteers. Wednesday 15:50-17:20 |
II-59 Fredrik Jonsson Exposure-Response Modeling of Emicizumab for the Prophylaxis of Bleeding in Hemophilia A Patients Wednesday 15:50-17:20 |
II-72 Hyungsub Kim Pharmacokinetic and pharmacodynamic modeling of 10% intravenous immunoglobulin and glucocorticoids for adult patients with immune thrombocytopenia Wednesday 15:50-17:20 |
III-08 Magnus Åstrand Longitudinal pharmacometric modelling of serum potassium lowering effect of sodium zirconium cyclosilicate in patients with hyperkalemia Thursday 09:55-11:30 |
III-19 Carla Bastida Fernández PK/PD of the individual components of composite indexes variables used for disease activity assessment in rheumatoid arthritis patients on tocilizumab treatment. Thursday 09:55-11:30 |
III-21 Amina Bensalem Concentration-effect relationships of therapeutic monoclonal antibody rituximab in rheumatoid arthritis. Thursday 09:55-11:30 |
III-26 Alessandro Boianelli A quantitative systems pharmacology model for understanding the role of dietary fructose metabolism in NAFLD Thursday 09:55-11:30 |
III-27 Charlotte Bon Capacity limits of ASGPR mediated liver targeting Thursday 09:55-11:30 |
III-35 Wonkyung Byon Apixaban for treatment of venous thromboembolism (VTEtx): Use of Model-Based Meta-Analysis (MBMA) to support Phase 3 dose selection and beyond Thursday 09:55-11:30 |
III-38 Marc Cerou HAM-D score analysis of patients under placebo with major depressive disorder using item response theory Thursday 09:55-11:30 |
III-40 Dong Woo Chae Predictive Modeling of PCA Effect on Postoperative Pain Management Thursday 09:55-11:30 |
III-63 Nico de Jager Population pharmacokinetic modelling of factor VIII levels during perioperative dosing of Haemate® P (Humate P) in patients diagnosed with von Willebrands Disease. Thursday 09:55-11:30 |
III-74 Erwin Dreesen Development of a population pharmacokinetic and pharmacodynamic model to describe the effect of infliximab induction therapy on mucosal healing in patients with ulcerative colitis Thursday 09:55-11:30 |
III-77 Salvatore D'Agate Development of a drug-disease model describing individual IPSS trajectories in BPH patients: Implication of disease progression and covariate factors on long term treatment response Thursday 09:55-11:30 |
IV-02 Shankar Lanke Population Pharmacokinetic Analyses of Tolvaptan in Subjects with Autosomal Dominant Polycystic Kidney Disease Thursday 15:10-16:40 |
IV-13 Rasmus Jansson Löfmark Pharmacokinetic population modelling of a GLP1 beta cell targeting oligonucleotide Thursday 15:10-16:40 |
IV-15 Qiang Lu Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma Thursday 15:10-16:40 |
IV-18 Lei Ma Efpeglenatide dose selection for a phase 3 study in type 2 diabetes mellitus (T2DM) patients: pharmacokinetics and pharmacodynamics (PK/PD) modeling, network meta-analysis and clinical trial simulation Thursday 15:10-16:40 |
IV-19 Matthias Machacek A Systems Pharmacology model of peripheral serotonin production proposing two different synthesis compartments with markedly different release rates into blood Thursday 15:10-16:40 |
IV-43 Boram Ohk Population pharmacokinetics of sumatriptan in healthy korean subjects : sex differences Thursday 15:10-16:40 |
IV-53 Christophe Passot Therapeutic drug monitoring of eculizumab in atypical hemolytic uremic syndrome Thursday 15:10-16:40 |
IV-64 Jens Przybilla Epigenetic modelling of DNA demethylation therapy in Acute Myeloid Leukemia Thursday 15:10-16:40 |
IV-66 Luis Quintairos Domenech Pharmacodynamic modelling of biomarkers in kidney transplantation: a transformed binary data population approach Thursday 15:10-16:40 |
IV-69 François Riglet Multiple response modelling of mycophenolic acid pharmacokinetics in adult patients with transplanted kidneys by population approach Thursday 15:10-16:40 |
IV-72 Leire Ruiz Cerdá External validation of Systems Pharmacology Models of the Coagulation Network with published data Thursday 15:10-16:40 |
IV-76 Stephan Schaller Towards Predictions of Clinical Trial Outcomes: Combining PBPK and QSP within a Translational Diabetes Disease Platform Thursday 15:10-16:40 |